During the past decade, The Second Hospital of Tianjin Medical University conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 7 clinical trials were completed, i.e. on average, 14.6% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 5 clinical trials were completed. i.e. 16.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Second Hospital of Tianjin Medical University" #1 sponsor was "Tianjin Medical University Second Hospital" with 20 trials, followed by "Pfizer" with 5 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Second Hospital of Tianjin Medical University" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Jiangsu HengRui Medicine Co., Ltd." with 2 trials as a collaborator, "Jiangsu Suzhong Pharmaceutical Group Co., Ltd." with 2 trials as a collaborator, "Tianjin Medical University General Hospital" with 2 trials as a collaborator and "Affiliated Hospital of Hebei University" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "The Second Hospital of Tianjin Medical University" are "Prostate Cancer" (5 trials), "Urothelial Carcinoma" (3 trials), "Antineoplastic Agents" (2 trials), "Castration-resistant Prostate Cancer" (2 trials) and "Clear Cell Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "The Second Hospital of Tianjin Medical University" in a lesser frequency.

Most popular intervention types in "The Second Hospital of Tianjin Medical University" are "Drug" (47 trials), "Other" (6 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Tislelizumab" (3 trials), "Abemaciclib" (2 trials), "Axitinib" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Second Hospital of Tianjin Medical University" are 41 trials for "All" genders, 11 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "The Second Hospital of Tianjin Medical University". 5 are not yet recruiting, 17 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in The Second Hospital of Tianjin Medical University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Second Hospital of Tianjin Medical University, 3 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 4 trials that are defined as “Not Applicable".